AI assistant
CEL SCI CORP — Director's Dealing 2020
Apr 20, 2020
34401_dirs_2020-04-20_ba475199-56c1-453b-a490-f99ec4149f18.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CEL SCI CORP (CVM)
CIK: 0000725363
Period of Report: 2020-04-20
Reporting Person: KERSTEN GEERT R (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-04-20 | Options | $10.93 | A | 592000 | Acquired | 2030-04-19 | Common Stock (592000) | Direct |
Footnotes
F1: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days.